Primary N-hydroxylamines
AssigneeThe Regents of the University of California
InventorsBruce N. Ames, Hani Atamna
Life of this patent
Estimating the term…
Abstract
The invention provides pharmaceutical compositions comprising primary N-hydroxylamines and related therapeutic, prophylactic, diagnostic and screening methods. The pharmaceutical compositions generally comprise a pharmaceutical composition comprising an orally administrable effective unit solid dosage of a primary N-hydroxylamine or a pharmaceutically acceptable salt thereof and substantially free of a nitrone corresponding to the hydroxylamine.
Claims62
A pharmaceutical composition comprising an orally administrable effective unit solid dosage of a primary N-hydroxylamine or a pharmaceutically acceptable salt thereof and substantially free of a nitrone corresponding to the hydroxylamine, wherein the hydroxylamine has the general formula,
- NHOHCR1R2R3
- wherein R1, R2 and R3 are independently selected from:
- substituted or unsubstituted (C0-C10) alkyl, alkenyl, alkynyl, aryl, oxyl, acyl, carboxyl, amino, nitro, nitroso, oxime, hydrazone, azo, thiol, sulfonyl and halide.
A method for reducing oxidative damage to, or delaying senescence of a cell comprising the steps of:
- identifying a cell as subject to or at risk of undesirable oxidative damage or senescence;
- and
- contacting the cell with a composition comprising an effective amount of a primary hydroxylamine and substantially free of a nitrone corresponding to the hydroxylamine.
A method for screening for primary N-hydroxylamines which reduce oxidative damage to, or delay senescence of cells, comprising the steps of:
- contacting cells with a candidate primary N-hydroxylamine under conditions whereby, but for the presence of the hydroxylamine, the cells present a reference amount of oxidative damage or senescence;
- detecting post-treatment amounts of oxidative damage or senescence of the cells;
- wherein a lesser amount of post-treatment than reference amounts of oxidative damage or senescence indicates that the hydroxylamine reduces oxidative damage or delays senescence of the cells.
Dependencies are inferred from the claim text.